{"id":"W2327624302","doi":"10.1093/neuonc/nou255.12","title":"ET-12 * PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERSUS PLACEBO PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA","year":2014,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Bevacizumab; Medicine; Clinical endpoint; Internal medicine; Placebo; Oncology; Phases of clinical research; Adverse effect; Gastroenterology; Surgery; Chemotherapy; Clinical trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000270983,0.0004551321,0.001190089,0.0004821985,0.0001269746,0.00001274244,0.0002166574,0.000205076,0.0001108121],"category_scores_gemma":[0.00034891,0.0003341734,0.0001213861,0.000412795,0.0001266816,0.0001108168,0.0002252152,0.0004914806,0.00003546362],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001319929,"about_ca_system_score_gemma":0.0005379846,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001074532,"about_ca_topic_score_gemma":0.002186153,"domain_scores_codex":[0.9966853,0.0005080663,0.0007510943,0.0007844061,0.0006866254,0.0005845377],"domain_scores_gemma":[0.9975864,0.0007714549,0.0004046691,0.0007250009,0.0002153562,0.0002971348],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4986705,0.1245657,0.04831381,0.0002256914,0.001108797,0.002148364,0.01494019,0.001101684,0.002210334,0.0003501074,0.003431557,0.3029333],"study_design_scores_gemma":[0.4976614,0.4451548,0.03270119,0.0001464748,0.0007522679,0.0000565688,0.0009920989,0.0009538967,0.001770264,0.00001272592,0.01935874,0.000439577],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940221,0.00005385129,0.000004640677,0.0007886459,0.0008396765,0.002794313,0.00002884803,0.00007182918,0.001396122],"genre_scores_gemma":[0.9989905,0.00001814281,0.00009242158,0.0002766626,0.00008277645,0.0004005936,0.00006060628,0.00006473393,0.00001356174],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.320589,"threshold_uncertainty_score":0.999911,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02235071206839599,"score_gpt":0.3150840269654915,"score_spread":0.2927333148970955,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}